You are here

Category
Technology Name
Briefcase
Scientist
1431
A method to monitor the amount of milk consumed by the baby during breastfeeding.Breastfeeding has been shown to have important health advantages for both baby and mother. A few months of exclusive breastfeeding has been shown to reduce the risk of infant gastro-intestinal problems, respiratory,...

A method to monitor the amount of milk consumed by the baby during breastfeeding.

Breastfeeding has been shown to have important health advantages for both baby and mother. A few months of exclusive breastfeeding has been shown to reduce the risk of infant gastro-intestinal problems, respiratory, urinary tract and ear infections. Furthermore, adults who were breastfed at infancy have a lower propensity for obesity, high cholesterol levels and high blood pressure – all risk factors for heart disease. Despite these advantages less than 50% continue breastfeeding beyond 4 weeks. The most common reason given for not breastfeeding or breastfeeding less than three months is ‘not enough milk’. The perception that milk production is insufficient however is subjective. At present, the only method to monitor the amount of milk a baby eats is by weighing the baby before and after feeding. The current technology can monitor amount and quality of milk during breastfeeding.

Applications


Monitoring of the amount of milk given while breastfeeding

Advantages


·        This method allows measuring both milk quantity and quality

  • Encourage infant breastfeeding.
  • Measurement of capacitance with no electrical contact between the electrodes and the body

Technology's Essence


The outlined technology consists of monitoring the amount of milk consumed by a baby during breastfeeding by measuring the capacitance between electrodes placed on the breast (but not in electrical contact with them) during feeding. It is sensitive to the amount, dielectric properties and distribution of matter in the immediate neighborhood of the capacitor plates. When placed on the breasts the capacitance is affected by the amount and properties of materials between plates, including milk content and constitution. Thus, if the amount of milk in the breast is reduced during breastfeeding the capacitance changes accordingly.

+
  • Ph.D. Ruti Kapon
1698
GD is an inherited metabolic disorder, affecting about 1 in 20,000 births. GD is divided into three clinical subtypes: type 1 is the most common and is characterized by bruising, fatigue, anemia, low blood platelets, and enlargement of the liver and spleen. Types 2 and 3, also called neuronopathic GD (...

GD is an inherited metabolic disorder, affecting about 1 in 20,000 births. GD is divided into three clinical subtypes: type 1 is the most common and is characterized by bruising, fatigue, anemia, low blood platelets, and enlargement of the liver and spleen. Types 2 and 3, also called neuronopathic GD (nGD), affect 4% of GD patients and additionally include neurological symptoms. Type 1 patients can have a normal life expectancy if treated whereas type 2/3 patients do not survive to reach adulthood. Moreover, GD carriers, approximately 1% of the population, are in a major risk of developing Parkinson’s disease. Current therapies suffer from severe drawbacks in the treatment of type 1 GD and no therapy exists that effectively treat nGD. The present technology offers a novel therapeutic target for the treatment of Gaucher's disease (GD) which addresses also the neurological symptoms.

Applications


  • Alternative treatment for type 1 GD
  • First line therapy for nGD

Advantages


  • A novel therapy for nGD which has no treatment for the present.
  • A novel therapeutic approach for GD type 1, via a previously unknown molecular mechanism.
  • Allows the development of an orally administered treatment, far more convenient for the patients than the existing treatments.
  • Reduced costs compared to the existing therapies of ERP or BMT

Technology's Essence


The proposed technology is based on the discovery that RIP3 is a key player in the manifestation of GD and that inhibiting RIP3 activity is effectively ameliorating the symptoms of GD not only in the less severe type 1 but also in the neuropathic form of the disease, types 2 and 3. nGD is associated with a massive neuronal loss and elevated RIP3 levels. Inhibition of RIP3 in a mouse model of nGD resulted in a dramatic attenuation of disease signs: drastic extension of life span, no weight loss, improvements in motor coordination, reduced neuroinflammation and improved liver and spleen injuries.

+
  • Prof. Anthony H. Futerman

Pages